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ABSTRACT:
mRNA X Dynamic RNA
nanotechnology
mRNA Y
Dynamic RNA nanotechnology with small conditional RNAs (scRNAs) o↵ers a promising con-
ceptual approach to introducing synthetic regulatory links into endogenous biological circuits.
Here, we use human cell lysate containing functional Dicer and RNases as a testbed for engi-
neering scRNAs for conditional RNA interference (RNAi). scRNAs perform signal transduction
via conditional shape change: detection of a subsequence of mRNA input X triggers formation
of a Dicer substrate that is processed to yield siRNA output anti-Y targeting independent mRNA Y for destruction. Automated
sequence design is performed using the reaction pathway designer within NUPACK to encode this conditional hybridization cascade
into the scRNA sequence subject to the sequence constraints imposed by X and Y. Because it is diﬃcult for secondary structure
models to predict which subsequences of mRNA input X will be accessible for detection, here we develop the RNAhyb method to
experimentally determine accessible windows within the mRNA that are provided to the designer as sequence constraints. We demon-
strate the programmability of scRNA regulators by engineering scRNAs for transducing in both directions between two full-length
mRNAs X and Y, corresponding to either the forward molecular logic “if X then not Y” (X a Y) or the reverse molecular logic “if Y
then not X” (Y a X). In human cell lysate, we observe a strong OFF/ON conditional response with low crosstalk, corresponding to
a ⇡20-fold increase in production of the siRNA output in response to the cognate vs non-cognate full-length mRNA input. Because
diverse biological pathways interact with RNA, scRNAs that transduce between detection of endogenous RNA inputs and production
of biologically active RNA outputs hold great promise as a synthetic regulatory paradigm.
KEYWORDS: small conditional RNA (scRNA), conditional siRNA production, conditional RNAi, molecular programming, dy-
namic RNA nanotechnology, human cell lysate, RNA degradation, Dicer processing
Over the last 15 years, researchers in the emerging disci-
pline of dynamic DNA nanotechnology have developed strik-
ing capabilities for engineering pathway-controlled hybridiza-
tion cascades in which small conditional DNAs (scDNAs) ex-
ecute dynamic functions by autonomously performing inter-
actions and conformation changes in a prescribed order.1,2
These mechanisms are powered by the enthalpy of base-
pairing and the entropy of mixing, exploiting diverse design
elements to e↵ect assembly, disassembly, and pathway control
(Figure 1a). While considerable e↵ort has been invested in
exploring dynamic DNA nanotechnology in a test tube, com-
paratively little attention has been paid to dynamic RNA
nanotechnology, which o↵ers profound opportunities for in-
troducing synthetic regulatory links into living cells and or-
ganisms. We envision small conditional RNAs (scRNAs) that
interact and change conformation to transduce between de-
tection of an endogenous programmable input, and produc-
tion of a biologically active programmable output recognized
by an endogenous biological pathway (Figure 1b). In this sce-
nario, the input controls the scope of regulation and the out-
put controls the target of regulation, with the scRNA lever-
aging programmability and conditionality to create a logical
link between the two.
As a motivating example, consider conventional RNA inter-
ference (RNAi), which o↵ers the benefit of programmability,
but lacks conditionality. RNAi mediated by small interfering
RNAs (siRNAs) enables knockdown of a gene of choice,3,4 ex-
ecuting the molecular logic: silence gene Y. Because siRNAs
are constitutively active, it is diﬃcult to confine silencing to
a subset of the cells under study (e.g., Figure 1c top). To en-
able cell-selective silencing, we envision scRNAs that mediate
“conditional RNAi” corresponding to the molecular logic: if
gene X is transcribed, silencing independent gene Y. Upon
detection of mRNA input X, the scRNAs perform shape and
sequence transduction to form a Dicer substrate that is pro-
cessed by Dicer to yield siRNA output anti-Y targeting an
independent mRNA Y for destruction. In this scenario, Y
would be silenced only in tissues where X was expressed (e.g.,
Figure 1c bottom).
Several groups have made contributions5–9 toward the still
outstanding goal of engineering scRNAs that perform shape
and sequence transduction to implement conditional RNAi
(X a Y). In this endeavor, we previously developed five
scRNA mechanisms for conditional Dicer substrate forma-
tion, each exploiting a di↵erent combination of design ele-
ments from Figure 1a.8 In the presence of full-length mRNA
input X, these mechanisms produce an OFF/ON conditional
response yielding an order of magnitude increase in produc-
tion of a Dicer substrate targeting independent mRNA Y.
By appropriately dimensioning and/or chemically modifying
the scRNAs, only the product of signal transduction, and
not the reactants or intermediates, was eﬃciently processed
by Dicer, yielding siRNA outputs anti-Y. In broad terms, this
work demonstrated that design elements previously developed
and explored in the context of dynamic DNA nanotechnology
could be adapted for dynamic RNA nanotechnology, provid-
ing a molecular vocabulary for pursuing the regulatory goals
of Figure 1b.
The simplest and most promising of these mechanisms em-
ployed a duplex scRNA A·B, which upon detecting mRNA
input X, produced an shRNA Dicer substrate B that is pro-
cessed by Dicer to yield siRNA output anti-Y (Figure 1d).8
With this scRNA mechanism, X partially displaces A from B
via toehold-mediated 3-way branch migration (Step 1a), ex-
posing a previously sequestered internal toehold, ‘c’, within
B, mediating a further 3-way branch migration (Step 1b) that
promotes spontaneous dissociation of B from X·A to yield
shRNA Dicer substrate B. This mechanism has the desirable
property that the scRNA A·B is stable rather than metastable
(i.e., if scRNAs are allowed to equilibrate in the absence of
X, they will predominantly remain in the A·B reactant state
rather than producing product shRNA B).8 Hence, there is a
thermodynamic rather than a kinetic limit on the amount of
spurious output that will be produced in the absence of input,
providing the conceptual basis for engineering a clean and
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Figure 1. Dynamic RNA nanotechnology for programmable conditional regulation with small conditional RNAs (scRNAs). (a) Design
elements for dynamic RNA nanotechnology. (b) Opportunities for programmable conditional regulation via scRNA signal transduction.
(c) Molecular logic of conventional RNAi (“not Y”; a Y) vs. conditional RNAi (“if X then not Y”; X a Y). In this conceptual illustration,
conventional RNAi silences Y in all tissues, while conditional RNAi silences Y only in tissues where and when X is expressed, exerting
spatiotemporal control over regulation. (d) scRNA mechanism implementing molecular logic X a Y. scRNA A·B detects mRNA input
X (containing subsequence ‘a-b-c’), leading to production of shRNA Dicer substrate B that is processed by Dicer to produce siRNA
output anti-Y (targeting mRNA silencing target Y containing subsequence ‘y-z’). scRNA A·B is stable in the absence of X. X partially
displaces A from B via toehold-mediated 3-way branch migration, exposing a previously sequestered internal toehold, ‘c’, within B (Step
1a). Internal nucleation of duplex ‘c/c*’ within B mediates a further internal 3-way branch migration to form duplex ‘z/z*’, facilitating
disassembly of B from X·A via spontaneous dissociation of short duplex ‘y/y*’ (Step 1b). Dicer processing of the resulting canonical
shRNA Dicer substrate, B, yields siRNA output anti-Y (with guide strand ‘z*-y*’). Domain lengths: |a| = 16, |b| = 14, |c| = 5, |y| =
2, |z| = 19. RNA strands denoted by uppercase letters, sequence domains denoted by lowercase letters with complementarity indicated
by ‘*’. 32P internal radiolabel denoted by dot on B strand. Chemical modifications (20OMe-RNA): A (dashed backbone), B (50 and 30
nucleotides only).
reliable OFF state. When we measured the OFF/ON con-
ditional response for production of shRNA B in a test tube,
the OFF state was undetectable (i.e., smaller than the gel
quantification uncertainty), illustrating the benefits of using
a stable scRNA. The OFF/ON conditional response with a
full-length mRNA input X was >50-fold. On the other hand,
using a short RNA input Xs corresponding to only the por-
tion of the mRNA that binds the scRNA, the OFF/ON ratio
was >200-fold, suggesting that the secondary structure of the
full-length mRNA inhibited interactions with the scRNA to
some degree.8
Here, as a stepping stone toward validating scRNA sig-
nal transduction in living cells and organisms, we tested
this scRNA mechanism in human cell lysate. Compared to
our previous test tube studies in bu↵er using recombinant
Dicer, lysate with functional endogenous Dicer10 more closely
mimics the cellular environment, as it includes cellular pro-
teins and nucleic acids that can inhibit scRNA function, and
RNases that can degrade the scRNAs (we specifically avoided
adding RNase inhibitors to the lysate in order to preserve the
challenge of overcoming RNase-mediated degradation). No-
tably, working in lysate eliminates the need to deliver scRNAs
across the cell membrane, removing a potential failure mode
in order to focus attention on the performance of the signal
transduction mechanism itself.
Our previous experiments were performed using scRNAs
and full-length mRNA inputs at 0.5 µM in bu↵er, assayed
with native polyacrylamide gel electrophoresis and fluores-
cent staining. Because previous RNAi studies suggest the
need for an siRNA concentration in the range of 0.1-10 nM
within the cell for e↵ective gene knockdown in vivo,11,12 we
set out to test scRNA A·B at 2.5 nM in our lysate studies. To
provide the sensitivity needed for gel assays at this low con-
centration, as well as to discriminate between scRNA-derived
and lysate-derived nucleic acids, we radio-labeled strand B
with 32P (Section S1.2), enabling tracking of state changes
between: 1) duplex scRNA A·B, 2) monomer shRNA Dicer
substrate B, 3) Dicer-processed siRNA output anti-Y, and
4) RNase-mediated degradation of B. The full-length mRNA
input X (or short RNA input Xs) was introduced at 4⇥ the
scRNA concentration. With scRNAs at the low 2.5 nM con-
centration in bu↵er, we observed strong conditional produc-
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tion of shRNA B in response to short RNA input Xs but
minimal response to the full-length mRNA input X (Fig-
ure S4a). Furthermore, in human cell lysate, the response
to the short RNA input Xs was substantially weakened, and
there was negligible response to the full-length mRNA input
X (Figure S4b). These initial failures provided the embarka-
tion point for the present work, in which we use human cell
lysate as an engineering testbed to optimize scRNA perfor-
mance for full-length mRNA detection at low concentration
in the presence of cellular proteins, nucleic acids, and RNases.
These initial results suggested the need to re-dimension
the scRNA sequence domains to optimize the energetics of
the mechanism for detection of full-length mRNA input X at
low concentration in lysate. Over several rounds of sequence
design and experimental testing, we made the following ad-
justments to scRNA A·B: 1) increased toehold ‘a’ by 4 nt
to enhance nucleation between A·B and X and better me-
diate subsequent partial opening of duplex A·B via toehold-
mediated 3-way branch migration (Step 1a), 2) increased du-
plex ‘c/c*’ by 2 bp to enhance self-nucleation within B and
better mediate subsequent further opening of duplex A·B via
toehold-mediated 3-way branch migration (Step 1b), 3) ad-
dition of 2-nt duplex ‘y/y*’ to A·B to require spontaneous
dissociation of B from A·B to reduce spurious production of
shRNA B in the absence of input mRNA X.
For each design cycle with new scRNA domain dimensions,
sequence design was performed using the reaction pathway
designer within NUPACK;13,14 sequence design was formu-
lated as a multistate optimization problem using target test
tubes to represent reactant, intermediate, and product states
along the reaction pathway (Figure 2a).14 Each target test
tube contains the depicted on-target complexes correspond-
ing to the on-pathway products for a given step (each with
the depicted target structure and a target concentration of
2.5 nM) as well as o↵-target complexes (all complexes of
up to 4 strands, each with a target concentration of 0 nM;
not depicted) corresponding to on-pathway reactants and o↵-
pathway crosstalk for a given step.
Sequence design is performed subject to complementarity
constraints inherent to the reaction pathway (Figure 1d; do-
main ‘b’ complementary to ‘b*’, etc), as well as to biological
sequence constraints imposed by the mRNA input X and the
mRNA silencing target Y. For the current scRNA mechanism,
every nucleotide in the design is constrained to be a subse-
quence of either X or Y (see constraint shading in Figure 2a),
reflecting the simplicity of the mechanism, and placing severe
demands on sequence design.
The sequence is optimized by reducing the ensemble de-
fect, quantifying the average fraction of incorrectly paired
nucleotides over the multi-tube ensemble.14,17,18 Optimiza-
tion of the ensemble defect implements both a positive de-
sign paradigm, explicitly designing for on-pathway elemen-
tary steps, and a negative-design paradigm, explicitly de-
signing against o↵-pathway crosstalk. The ensemble defect
can be decomposed into two types of contribution: “struc-
tural defect” (fraction of nucleotides in the incorrect base-
pairing state within the ensemble of the on-target complex)
and “concentration defect” (fraction of nucleotides in the in-
correct base-pairing state because there is a deficiency in the
concentration of the on-target complex).
Figure 2b displays the target test tubes for a completed
sequence design of the redimensioned scRNA A·B. Concen-
tration defects are negligible (each on-target complex forms
with quantitative yield at the desired 2.5 nM target concen-
tration). On the other hand, the structural defect is above
6% for scRNA A·B (see probability shading in Figure 2b indi-
cating undesired base-pairs between toeholds ‘a*’ and ‘z’ with
probability greater than zero) and for intermediate Btruncate
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Figure 2. Computational scRNA sequence design using NU-
PACK. (a) Sequence design is formulated as a multistate opti-
mization problem using target test tubes to represent reactant,
intermediate, and product states along the reaction pathway (Fig-
ure 1d).13,14 Each target test tube contains the depicted on-target
complexes corresponding to the on-pathway products for a given
step (each with the depicted target structure and a target concen-
tration of 2.5 nM) as well as o↵-target complexes (all complexes
of up to 4 strands, each with a target concentration of 0 nM; not
depicted) corresponding to on-pathway reactants and o↵-pathway
crosstalk for a given step. The Intermediate tube (Step 1a) con-
tains a truncated version of strand B to facilitate design of the
‘c/c*’ self-nucleation duplex. Every nucleotide in the design is
constrained by the sequence of either the mRNA input X or the
mRNA silencing target Y (see domain shading). (b) Analysis of
design quality over the design ensemble.13,15 Tubes depict the
predicted concentration and target structure for each on-target
complex, with nucleotides shaded to indicate the probability of
adopting the depicted base-pairing state at equilibrium. For this
design, all on-targets are predicted to form with quantitative yield
at the 2.5 nM target concentration (negligible concentration de-
fects) but some nucleotides have unwanted base-pairing interac-
tions (non-negligible structural defects for nucleotides not shaded
dark red). Bar graphs depict the residual defect for each on-target
complex in each tube (blue shading: structural defect component,
green shading: concentration defect component [negligible for this
sequence design]). RNA at 37 ◦C in 1 M Na+.16
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Figure 3. Conditional siRNA production via scRNA signal transduction in human cell lysate. (a) Forward molecular logic (X a Y):
if mRNA input X is detected, generate siRNA output anti-Y targeting mRNA Y for silencing. (b) Reverse molecular logic (Y a X): if
mRNA input Y is detected, generate siRNA output anti-X targeting mRNA X for silencing. (a,b) scRNA signal transduction in lysate
(HEK 293T) that is either Dicer-depleted (–) or wildtype (wt; containing endogenous Dicer). Strand B internally radiolabeled with 32P
(dot in Figure 1d) to enable native PAGE assay with scRNA at 2.5 nM; mRNA input spiked into lysate at ⇡10 nM. OFF state: minimal
production of siRNA output in the absence of mRNA input (lanes 1, 2) or in the blocked state where the mRNA input is pre-incubated
with a blocker strand L that binds to the scRNA nucleation site on the mRNA (lanes 5, 6). ON state: strong production of siRNA
output in the presence of mRNA input (lanes 3, 4). shRNA B provides a control illustrating Dicer processing to generate siRNA output
(lanes 7, 8). siRNA size markers (lane 9).
(indicating desired base-pairs in duplex ‘c/c*’ with probabil-
ity less than one). These defects reflect the real-world chal-
lenges of designing sequences that execute a dynamic reaction
pathway, yet are fully constrained by the sequences of mR-
NAs X and Y.
Operating at 2.5 nM in human cell lysate, the re-
dimensioned scRNA exhibits strong OFF/ON conditional
siRNA production (Figure 3a). In the absence of mRNA in-
put X, there is minimal production of siRNA output anti-Y
(lane 2), while in the presence of X, there is strong production
of anti-Y (lane 4). To verify that siRNA production is Dicer
mediated, we depleted Dicer from the lysate (Dicer knock-
down in cells using an siRNA pool followed by lysate immun-
odepletion with an anti-Dicer antibody). The Dicer-depleted
lysates show minimal siRNA production (lanes 1 and 3) rela-
tive to wildtype lysates (lanes 2 and 4), producing shRNA B
instead of siRNA anti-Y as the product of signal transduction.
To verify that A·B signal transduction is triggered by the in-
tended subsequence of mRNA input X, we pre-incubated X
with an 20OMe-RNA blocker strand, LX, that binds to the
nucleation site, ‘a’, on X (lanes 5 and 6), e↵ectively blocking
interaction with A·B and restoring the OFF state (cf. lanes
1 and 2).
The data of Figure 3a demonstrate conditional siRNA pro-
duction for the forward molecular logic “if X then not Y”
(X a Y), where X is a full-length mRNA input and Y is an
independent mRNA silencing target. With the intention of
demonstrating the programmability of scRNA signal trans-
duction, we repeated sequence design for the reverse molec-
ular logic “if Y then not X” (Y a X), using Y as the mRNA
input and X as the mRNA silencing target. For multiple se-
quence designs, we ran into the diﬃculty that the designed
scRNAs functioned properly in detecting the short RNA in-
put Ys (the targeted subsequence of Y), but were ine↵ective
in detecting the full-length mRNA input Y (see two examples
in Figures S5 and S6). This failure mode highlights the inher-
ent diﬃculty in attempting to engineer scRNAs that detect
full-length mRNAs. The RNA secondary structure model16
underlying NUPACK is not as accurate for predicting struc-
tural properties of (long) mRNAs as for (short) scRNAs, pre-
sumably due to a combination of pseudoknotting, long-range
tertiary interactions, and (in lysate) protein/RNA interac-
tions – none of which are accounted for in the physical model.
In e↵ect, the sequence design pipeline succeeds in engineering
the portion of the problem that is present in the model, but
it fails to overcome the challenges of mRNA structure that
are omitted from the model.
After repeatedly encountering this problem while attempt-
ing to engineer the reverse logic Y a X, we came to realize that
mRNA accessibility is a major issue that should be addressed
experimentally as a pre-processing step prior to sequence de-
sign. To measure base-pairing accessibility directly, we devel-
oped a simple cost-e↵ective method, termed “RNAhyb”, that
measures hybridization between a full-length mRNA and in-
dividual 20-nt 32P-labeled DNA probes that each bind to a
di↵erent subsequence along the mRNA (see Section S6). We
discovered that most 20-nt windows within mRNA Y are rel-
atively inaccessible (<10% hybridization yield) and that the
most accessible regions permit hybridization yields of 20-40%
(Figure 4). Using RNAhyb, we identified a 150-nt window of
mRNA Y that is relatively accessible. We then provided NU-
PACK with this accessible window as a sequence constraint
in place of full-length mRNA Y.
The resulting NUPACK sequence design yielded an scRNA
A·B that successfully detected full-length mRNA input Y.
However, fixing the mRNA accessibility issue revealed a new
degradation issue, as the functional scRNA A·B for reverse
logic Y a X was rapidly degraded by RNases in the lysate
(Figure S15). Interestingly, we had not observed this degra-
dation issue to nearly the same degree with the forward logic
scRNA (Figure S16). To this point, both in previous work8
and for the forward logic X a Y, we had used a fully mod-
4
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/439273doi: bioRxiv preprint first posted online Oct. 11, 2018; 
0 100 200 300 400 500 600 700 800 900 1000 1100
Position (nt)
0
0.1
0.2
0.3
0.4
Fr
ac
tio
n 
of
 p
ro
be
 b
ou
nd
Replicate 2
Replicate 3
Replicate 1
RNAhyb window provided to NUPACK
Subsequence chosen by NUPACK
RNAhyb: Measuring Accessibility of mRNA Input Y 
Figure 4. RNAhyb: experimental determination of mRNA accessibility. 20-nt DNA probe at 2.5 nM (labeled with 32P), mRNA input
Y at 10 nM. Total of 118 probes tested at 10 nt intervals along mRNA input Y to identify an accessible window for engineering reverse
logic mechanism (Y a X).
a b
scRNA: A•B
A•B
B
anti-X
ON:OFF
25 ± 2
0
0.2
0.4
0.6
0.8
1
siR
NA
s i
n 
lys
at
e
0.47
0.020.02
0.33
A•B
X Y X Y
B
A•B
anti-Y
ON
OFF OFF
ON
ON OFF OFF ON
ON:OFF
19 ± 4
mRNA input:
anti-Y anti-X
siRNA outputForward Reverse
scRNA orthogonality in lysate Quantification
siRNA 
output: scRNA: A•B A•B
X YmRNA input:
Forward Reverse
X Y
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man cell lysate. (a) Conditional siRNA production in the presence
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siRNA output anti-Y, non-cognate mRNA input Y) and reverse
logic (Y a X: cognate mRNA input Y, siRNA output anti-X, non-
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gels.
ified 20OMe-RNA A strand to prevent Dicer processing of
scRNA A·B, but an unmodified B strand to permit Dicer
processing of shRNA output B. Now, for the reverse logic
Y a X, we found that B was resistant to degradation as a
monomer shRNA but susceptible to degradation as part of
dimer scRNA A·B. To simultaneously prevent degradation of
A·B and maintain Dicer cleavage of shRNA B, we tested a
variety of chemical modifications to B. Conveniently, we dis-
covered that using a 1-nt 20OMe-RNA cap at either end of the
B strand, in conjunction with 20OMe-RNA for all of strand A
yielded the desired properties for the reverse mechanism (Fig-
ure S15) as well as for the forward mechanism (Figure S16).
Leveraging the mRNA accessibility sequence constraints
provided by RNAhyb in combination with the new scRNA
chemical modifications yields the reverse mechanism data
shown in Figure 3b. This scRNA executes the logic “if Y
then not X” (Y a X) with nearly the same characteristics
as the initial X a Y mechanism. In the OFF state, scRNA
A·B produces minimal shRNA B (lane 1) or siRNA output
anti-X (lane 2). In the ON state, scRNA A·B incubated with
full-length mRNA Y produces shRNA B (lane 3), which is
cleaved by Dicer into siRNA output anti-X (lane 4). Block-
ing the nucleation site on mRNA Y restores the OFF state
(lanes 5 and 6), demonstrating that scRNA signal transduc-
tion is triggered by the intended subsequence of mRNA input
Y.
Programmability, the ability to redesign scRNAs to inter-
act with mRNAs X and Y of choice, and orthogonality, the
ability to engineer scRNAs that operate independently with-
out crosstalk, are key conceptual goals of dynamic RNA nan-
otechnology. Both properties are highlighted in a side-by-side
demonstration of the forward system (X a Y) and reverse sys-
tem (Y a X) in Figure 5a. Each system produces a strong ON
state when presented with its cognate mRNA input (X for X
a Y; Y for Y a X), and a clean OFF state when presented with
the wrong input (Y for X a Y; X for Y a X) even though both
scRNAs are constrained by the sequences of both X and Y.
Quantification of the siRNA output bands for both forward
and reverse systems reveals a strong OFF/ON conditional
response with low crosstalk, corresponding to a ⇡20-fold in-
crease in production of the siRNA output in response to the
cognate vs non-cognate full-length mRNA input.
In the long run, we are working towards the goal of es-
tablishing a technology development pipeline for scRNA sig-
nal transduction in living organisms. Starting with a func-
tional goal for programmable conditional regulation (e.g.,
cell-selective gene silencing, gene activation, or cell death),
the first step is to decide which programmable input and en-
dogenous pathway to leverage (Figure 1b), followed by in-
vention of an scRNA signal transduction mechanism exploit-
ing design elements from dynamic RNA nanotechnology (Fig-
ure 1a), computational sequence design (Figure 2), and then
experimental validation in increasingly complex experimen-
tal settings: bu↵er, cell lysate, cell culture, and finally, liv-
ing organisms. Here, we established human cell lysate as an
scRNA testbed intermediate between the chemically pristine
environment of bu↵er in a test tube and the more challeng-
ing compartmentalized setting of the living cell. Radioac-
tive labeling of scRNA B allowed use of a biologically rele-
vant scRNA concentration (2.5 nM) in lysate containing cel-
lular proteins and nucleic acids including RNases. The lysate
environment enabled optimization of domain dimensions for
scRNAs that were functional in bu↵er but non-functional in
lysate as well as optimization of scRNA chemical modifica-
tions to inhibit o↵-pathway degradation while retaining on-
pathway Dicer processing. These design changes are likely
also necessary (but probably not suﬃcient) for scRNAs to
be functional in living cells, an environment where pathway
interrogation is much more diﬃcult.
While lysate o↵ers the key benefit of eliminating the need
for scRNA delivery, this simplicity comes with some draw-
backs. Any design challenges related to cellular compartmen-
talization are lost in lysate. Dilution of cellular components
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in lysate decreases protein and nucleic acid concentrations
below those in the cell, limiting our ability to characterize
o↵-target sequence e↵ects, and likely also contributing to our
inability to detect cellular mRNA inputs in lysate. Here, we
spiked in vitro transcribed mRNA inputs into the lysate.
mRNA accessibility was another important stumbling
block, limiting the utility of multiple scRNAs that performed
the intended signal transduction when presented with a short
RNA input, but failed to detect the same short sequence when
it was embedded in a full-length mRNA. To overcome this
diﬃculty, we developed the RNAhyb assay to directly char-
acterize the most accessible windows within an RNA input
as a pre-processing step prior to sequence design.
Automated scRNA sequence design was performed using
the NUPACK multistate designer subject to biological se-
quence constraints as well as those imposed by the dynamic
scRNA reaction pathway. With this approach, we achieved
conditional siRNA production with a ⇡20-fold OFF/ON re-
sponse in human cell lysate for both the forward molecular
logical X a Y and the reverse molecular logic Y a X, where
X and Y are full-length mRNAs. These results illustrate the
programmability and conditionality that make scRNA signal
transduction an alluring goal.
If the challenges of engineering and delivering scRNAs
in living organisms can be overcome, they o↵er the po-
tential to serve as powerful new research tools, leverag-
ing diverse endogenous pathways including RNAi5–9 and
CRISPR/Cas9.19,20 For example, conditional gene silencing
(“if gene X is transcribed, silence independent gene Y”) would
probe genetic necessity, conditional gene activation (“if gene
X is transcribed, activate independent gene Y”) would probe
genetic suﬃciency, and conditional cell death (“if gene X is
transcribed, induce apoptosis”) would probe developmental
compensation. In each case, conditional regulation would be
mediated by scRNAs that interact and change conformation
to transduce between detection of programmable input X and
activation of the desired regulatory output function. By se-
lecting a transcript X with desired spatial and temporal ex-
pression profiles, the regulatory function could be restricted
to a desired cell type, tissue, or organ within a model or-
ganism. To shift conditional regulation to a di↵erent tissue
or developmental stage, the scRNAs would be reprogrammed
to recognize a di↵erent input X. The same molecular logic
would have attractive therapeutic potential, with X as a pro-
grammable disease marker and the downstream regulatory
output chosen to be an independent therapeutic pathway, en-
abling selective treatment of diseased cells. Because of this
research and therapeutic potential, dynamic RNA nanotech-
nology for scRNA signal transduction merits significant engi-
neering e↵ort from the molecular programming and synthetic
biology research communities.
METHODS SUMMARY
Sequence design was performed using the reaction pathway
designer within NUPACK.13,14 Oligonucleotides (RNA and
20OMe-RNA) were synthesized and RNase-free HPLC puri-
fied by IDT. Target mRNAs were in vitro transcribed. Cell
lysates were made by sonication of HEK 293T cells. Dicer-
depleted lysates were generated by knocking down Dicer us-
ing an siRNA pool prior to lysis and Dicer immunodepletion
following lysis. 32P was incorporated in the backbone of B
to enable discrimination of scRNA reactants, intermediates,
and products from lysate nucleic acids, as well as to enable
gel assays at low concentration. scRNA A·B was PAGE pu-
rified as a duplex. scRNA signal transduction was tested by
incubating 2.5 nM scRNAs and 10 nM short RNA input or
full-length mRNA input in 1⇥ Bu↵er D or 1.25 µg/µL lysate
at 37 ◦C for 4 h. For experiments with a blocked nucle-
ation site, the mRNA input was pre-incubated with blocker
L. Reactions were separated by native PAGE and imaged via
autoradiography. RNAhyb was used to assay mRNA accessi-
bility using 20-nt 32P-labeled DNA probes at 10-nt intervals
along the mRNA input.
ASSOCIATED CONTENT
Detailed methods, RNAhyb protocol, sequences, motivating
failures, additional signal transduction studies for forward
and reverse mechanisms, RNAhyb studies, chemical modi-
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